Anti-tumor Effect of Antibody Drug With Venetoclax Plus Azacitidine in Acute Myeloid Leukemia



January 3, 2023

Oncotarget published this research paper in Volume 13, entitled, “Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model" by the researchers from Immuno-Oncology, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan and Applied Research and Operations, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan. DOI - Correspondence to - Hirofumi Tsuzuki - Sign up for free Altmetric alerts about this article - Keywords - acute myeloid leukemia (AML), ASP1235, antibody drug conjugate (ADC), venetoclax, azacitidine About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Cancer ResearchChemistryDrug DiscoveryMolecular Biology

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.